Category: <span>News</span>

iRes™2 CE certification
Post

iRes™2 CE certification

We are pleased to announce the CE approval on iRes™2, our fastest 2.0Khz excimer laser, empowering the smallest 350um laser micro-spot to execute iVis proprietary full automated, real-time controlled, no-touch, cTen® surgical procedure, maximizing surgical performance and avoiding intra-operative risks.

CIPTA®2 CE certification
Post

CIPTA®2 CE certification

We are pleased to announce the CE approval on CIPTA®2, the unique cloud-based software conceived for interactive ray-tracing customized corneal surgical planning

SafeCross®+ CE certification
Post

SafeCross®+ CE certification

We are pleased to announce the achievement of the CE mark on SafeCross®+ medical device on May 7th, 2021.

SafeCross®+ is a riboflavin ophthalmic solution, patented by iVis Technologies, granting  high cross-linking efficiency in poor oxygen environment.

iVis won EP’470 patent validity case against Schwind at the Board of Appeal of EPO
Post

iVis won EP’470 patent validity case against Schwind at the Board of Appeal of EPO

iVIS Technologies was granted the European patent EP 1 428 470 which relates to customized lamellar transplantations of corneal tissue for one of its early innovations. Such transplantations may be used to restore the vision of patients who suffer from corneal diseases such as keratokonus. A customized layer of the patient’s diseased cornea tailored according to patient’s needs is removed and replaced by a healthy layer of a donor cornea.

29 October 201929 October 2019by In News